Clinical trial · Interventional
Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer
NCT02327481CI-TRIAL-00065429completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the feasibility, safety, and efficacy of 3D Laparoscopic Surgery for Gastric Cancer. The patients with gastric adenocarcinoma (cT1-4aN0-3M0) were studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 2D Laparoscopic Surgery | Procedure | — | UNRESOLVED |
| 3D Laparoscopic Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 3D Laparoscopic Surgery
- description
- 3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
- interventionNames
- Procedure: 3D Laparoscopic Surgery
- type
- ACTIVE_COMPARATOR
- label
- 2D Laparoscopic Surgery
- description
- 2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
- interventionNames
- Procedure: 2D Laparoscopic Surgery
Primary outcomes (1)
- measure
- Operating time
- timeFrame
- 1 day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * (1)Age from over 19 to under 74 years * (2)cT1-4a(clinical stage tumor), N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition * (3)Heart, lungs, kidneys, and other vital organs function well, with no obvious surgical contraindications * (4)Preoperative examination with no distant metastasis, no significantly enlarged lymph nodes around the main abdominal artery, and tumor not a direct violation of the pancreas, spleen, and other surrounding organs * (5)American Society of Anesthesiology (ASA) score class I, II, or III * (6)Written informed consent Exclusion Criteria: * (1)Women during pregnancy or breast-feeding * (2)Severe mental disorder * (3)History of previous upper abdominal surgery (except laparoscopic cholecystectomy) * (4)Enlarged splenic hilar lymph nodes with integration into a mass and surrounding the blood vessels * (5)History of unstable angina or myocardial infarction within the past six months * (6)History of cerebrovascular accident within the past six months * (7)History of continuous systematic administration of corticosteroids within one month * (8)History of previous neoadjuvant chemotherapy or radiotherapy * (9)T4b tumors * (10)Emergency surgery due to complication (bleeding, obstruction, or perforation) caused by gastric cancer * (11)FEV1(Forced expiratory volume in one second)\<50% of predicted values
References
Publications (10)
- DERIVEDZhao W, Zhong Q, Li BL, Weng CM, Zhang HX, Wang G, Zhang ZQ, Wu YX, Wu D, Chen JY, Chen QY, Zheng CH, Huang CM, Xie JW. Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study. World J Surg Oncol. 2026 Jun 1;24(1):322. doi: 10.1186/s12957-026-04439-8. PMID 42226295
- DERIVEDWei LH, Zheng HL, Liu ZY, Du XQ, Chen CS, Xu BB, Zheng HH, Lin GT, Xie JW, Zheng CH, Wang JB, Huang CM, Li P. Preoperative visceral fat area predicts intraoperative adverse events during lymphadenectomy in laparoscopic gastrectomy for gastric cancer: a post hoc analysis. Surg Endosc. 2025 Apr;39(4):2275-2287. doi: 10.1007/s00464-025-11602-x. Epub 2025 Feb 12. PMID 39937241
- DERIVEDXu BB, Zheng HL, Chen CS, Xu LL, Xue Z, Wei LH, Zheng HH, Shen LL, Zheng CH, Li P, Xie JW, Lin JX, Zheng YH, Huang CM. Development and validation of a preoperative radiomics-based nomogram to identify patients who can benefit from splenic hilar lymphadenectomy: a pooled analysis of three prospective trials. Int J Surg. 2024 Jul 1;110(7):4053-4061. doi: 10.1097/JS9.0000000000001337. PMID 38980664
- DERIVEDZhong Q, Chen JY, Shang-Guan ZX, Liu ZY, Lin GT, Wu D, Jiang YM, Wang JB, Lin JX, Chen QY, Lin JL, Xie JW, Li P, Lu J, Huang CM, Zheng CH. Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial. Gastric Cancer. 2024 May;27(3):598-610. doi: 10.1007/s10120-024-01470-0. Epub 2024 Feb 20. PMID 38379100
- DERIVEDLiu ZY, Chen QY, Zhong Q, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Huang CM, Zheng CH. Intraoperative Adverse Events, Technical Performance, and Surgical Outcomes in Laparoscopic Radical Surgery for Gastric Cancer: A Pooled Analysis From 2 Randomized Trials. Ann Surg. 2023 Aug 1;278(2):222-229. doi: 10.1097/SLA.0000000000005727. Epub 2022 Oct 17. PMID 36250322
- DERIVEDLu J, Xu Y, Wu Y, Huang XY, Xie JW, Wang JB, Lin JX, Li P, Zheng CH, Huang AM, Huang CM. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer. BMC Cancer. 2019 Sep 14;19(1):920. doi: 10.1186/s12885-019-6089-z.